Key Highlights
- UroGen Pharma (NASDAQ:URGN) traded at USD 28.16, down 18.14% intraday on November 4, 2026, on the day it reported third quarter results and lowered its 2026 JELMYTO Revenue outlook.
- ZUSDURI net product revenue reached USD 68.0 million in the quarter, up 35% from the second quarter, while JELMYTO revenue fell to USD 21.0 million from USD 25.7 million a year earlier.
- The company cut 2026 JELMYTO guidance to about USD 90 million from USD 97 million to USD 101 million, citing a one-time CMS-related adjustment and competing trial enrollment.
- Net loss narrowed to USD 1.5 million from USD 33.3 million, but cash and marketable securities fell to USD 90.5 million and the Balance Sheet shows a shareholders' deficit.
What Moved UroGen Pharma During Trading (down USD 6.24, 18.14%)
UroGen Pharma (NASDAQ:URGN) was quoted at USD 28.16 intraday on November 4, 2026, down 18.14%. The implied prior close is USD 34.40 (calculated), so the decline equals USD 6.24 a share. Published market data showed about 617,480 shares changing hands, roughly 0.54 times the normal pace for the stock, and a market Capitalization near USD 1.38 billion. The timing points to the company release issued at 8:00 a.m. ET on November 4, 2026, followed by a conference call at 10:00 a.m. ET. Published coverage described total revenue as below analyst estimates; the consensus figure was not verified here. Heavy selling on lighter than usual Volume suggests holders reacted to the guidance change rather than to a broad rush of new buyers or sellers.
Inside the Third Quarter Results and the JELMYTO Guidance Cut
The company reported total third quarter revenue of USD 89.0 million, against USD 27.5 million a year earlier, with ZUSDURI contributing USD 68.0 million. ZUSDURI activated sites of care rose to 1,538 from 1,444 at June 30, 2026, unique prescribers climbed to 662 from 452, and repeat prescribers reached 331, about 50% of the total. JELMYTO sales were USD 21.0 million and included a one-time unfavorable gross-to-net adjustment of about USD 1.5 million. Management now expects 2026 JELMYTO net product revenue of about USD 90 million, down from USD 97 million to USD 101 million, pointing to that adjustment and competitive trial enrollment that affects low-grade upper tract urothelial cancer patient starts.
Balance Sheet, Pipeline and What Investors Weigh Next
Net loss was USD 1.5 million, or USD 0.03 a share, versus USD 33.3 million a year earlier. Cash, equivalents and marketable securities were USD 90.5 million at September 30, 2026, against USD 120.5 million at December 31, 2025, while total liabilities of USD 397.1 million exceeded total Assets of USD 271.9 million. Operating expenses are guided to USD 260 million to USD 270 million, toward the upper end. On the pipeline, the FDA accepted the UGN-103 application in October 2026 with a PDUFA goal date of June 14, 2027, and a Phase 3 trial in high-risk disease is planned to start in the fourth quarter. A guidance cut can pressure valuation because JELMYTO is a steady revenue base that supports Debt service while ZUSDURI scales.
Where Things Stand
The sell-off in UroGen Pharma (NASDAQ:URGN) appears tied to the November 4, 2026 results, where strong ZUSDURI growth was offset by a lower JELMYTO outlook and a thinner cash position. The next checkpoints are the 10-Q filing, the pace of ZUSDURI prescribers and site activations, and progress toward the June 14, 2027 UGN-103 decision date. Intraday moves can reverse as analysts update models after the call, and the stock remains sensitive to launch execution, reimbursement changes and competing trials.






Please wait processing your request...